metoprolol tartrate(redirected from Novo-Metoprol)
Pharmacologic class: Beta-adrenergic blocker (selective)
Therapeutic class: Antihypertensive, antianginal
Pregnancy risk category C
FDA Box Warning
• Exacerbations of angina pectoris and myocardial infarction (MI) may follow abrupt withdrawal of some beta blockers. When discontinuing long-term therapy, particularly in patients with ischemic heart disease, reduce dosage gradually over 1 to 2 weeks and monitor patient carefully. If angina worsens markedly or acute coronary insufficiency develops, reinstate drug promptly (at least temporarily) and take other appropriate measures to manage unstable angina. Caution patient not to interrupt or discontinue therapy without prescriber's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue drug abruptly even in patients treated only for hypertension.
Blocks stimulation of beta1 (myocardial) adrenergic receptors, usually without affecting beta2 (pulmonary, vascular, uterine) adrenergic receptor sites
Injection (tartrate): 1 mg/ml
Tablets: 50 mg, 100 mg
Tablets (extended-release, succinate): 25 mg, 50 mg, 100 mg, 200 mg
⊘Indications and dosages
Adults: 50 to 100 mg P.O. daily as a single dose or in two divided doses (conventional tablets) or once daily (extended-release tablets). May be increased q 7 days as needed, up to 450 mg/day (tartrate) or 400 mg (succinate extended-release).
➣ Angina pectoris
Adults: 100 mg P.O. daily as a single dose or in two divided doses (conventional tablets) or once daily (extended-release tablets). May be increased q 7 days as needed, up to 400 mg.
Adults: Three bolus injections of 5 mg I.V. given at 2-minute intervals. If patient tolerates I.V. dose, give 50 mg P.O. 15 minutes after last I.V. dose, and continue P.O. doses q 6 hours for 48 hours. For maintenance, 100 mg P.O. b.i.d. If patient doesn't tolerate full I.V. dose, give 25 to 50 mg P.O. (depending on degree of intolerance), starting 15 minutes after last I.V. dose or when clinical condition allows; discontinue drug if patient shows severe intolerance. As late treatment, 100 mg P.O. b.i.d. when clinical condition allows, continued for at least 3 months.
➣ Symptomatic heart failure
Adults: 25 mg P.O. daily (extended-release tablets) in patients with NYHA Class II heart failure. Dosage may be doubled q 2 weeks, up to 200 mg/day or until highest tolerated dosage is reached. For more severe heart failure, start with 12.5 mg P.O. daily.
• Ventricular arrhythmias, tachycardia
• Sinus bradycardia, heart block greater than first degree, cardiogenic shock, overt cardiac failure (with Lopressor used for hypertension or angina)
• Heart rate below 45 beats/minute, second- or third-degree heart block, significant first-degree heart block; systolic pressure below 100 mm Hg; or moderate-to-severe cardiac failure (when Lopressor is used for MI)
• Hypersensitivity to drug or its components, severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless permanent pacemaker is in place) (with Toprol-XL)
Use cautiously in:
• renal or hepatic impairment, pulmonary disease, diabetes mellitus, thyrotoxicosis
• MAO inhibitor use within past 14 days
• pregnant or breastfeeding patients
• children (safety not established).
• Give metoprolol tartrate with or immediately after meals, because food enhances its absorption.
• Know that succinate extended-release tablets are scored and can be divided. However, tablet or half-tablet should be swallowed whole and not crushed or chewed.
• For I.V. administration, give each dose undiluted by direct injection over at least 1 minute.
CNS: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares
CV: orthostatic hypotension, peripheral vasoconstriction, bradycardia, heart failure, pulmonary edema
EENT: blurred vision, stuffy nose
GI: nausea, vomiting, constipation, diarrhea, flatulence, gastric pain, heartburn, dry mouth
GU: urinary frequency, erectile dysfunction, decreased libido
Metabolic: hyperglycemia, hypoglycemia
Respiratory: wheezing, bronchospasm
Musculoskeletal: back pain, joint pain
Other: drug-induced lupus syndrome
Drug-drug.Amphetamines, ephedrine, epinephrine, norepinephrine, phenylephrine, pseudoephedrine: unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia)
Antihypertensives, nitrates: additive hypotension
Digoxin: additive bradycardia
Dobutamine, dopamine: reduced cardiovascular benefits of these drugs
General anesthestics, phenytoin (I.V.), verapamil: additive myocardial depression
Insulin, oral hypoglycemics: altered efficacy of these drugs
MAO inhibitors: hypertension
Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, glucose, lactate dehydrogenase, lipoproteins, potassium, triglycerides, uric acid: increased levels
Drug-food.Any food: enhanced drug absorption
Drug-behaviors.Acute alcohol ingestion: additive hypotension
Cocaine use: unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia)
• Measure blood pressure closely when starting therapy and titrating dosage. Once patient stabilizes, measure blood pressure every 3 to 6 months.
• Monitor blood pressure and pulse before I.V. administration. If patient is hypotensive or has bradycardia, consult prescriber before giving dose.
• Watch for orthostatic hypotension in at-risk patients, particularly the elderly.
• Assess glucose levels in diabetic patient. Be aware that drug may mask signs and symptoms of hypoglycemia.
• Monitor for signs and symptoms of hyperthyroidism. Know that drug may mask these. Reduce dosage gradually in hyperthyroid patients.
☞ When discontinuing drug, reduce dosage gradually over 1 to 2 weeks.
• Advise patient to take with or immediately after meals.
• Tell patient that extended-release tablets are scored and can be divided, but that he should swallow tablets or half-tablets whole and not crush or chew them.
☞ Advise patient with heart failure to report signs or symptoms of worsening condition, including weight gain and increasing shortness of breath.
• Caution patient to avoid driving and other hazardous activities until drug effects are known.
• Instruct patient to notify health care providers (including dentists) that he is taking drug before having surgery.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, foods, and behaviors mentioned above.
metoprolol tartrate(mĕ-tŏp′ră-lŏl″, -lōl″)
n brand name: Nu Metop;
drug class: antihypertensive selective β1-blocker;
action: produces fall in blood pressure without reflex tachycardia or significant reduction in heart rate;
uses: mild to moderate hypertension, acute myocardial infarction to reduce cardiovascular mortality, angina pectoris.